Stockscreener 앱 받기
163.63
0.18%
0.29
시간 외 거래:
163.63
전일 마감가:
$163.34
열려 있는:
$162.26
하루 거래량:
455.13K
Relative Volume:
0.61
시가총액:
$9.21B
수익:
$633.51M
순이익/손실:
$-8.10M
주가수익비율:
-527.84
EPS:
-0.31
순현금흐름:
$131.26M
1주 성능:
+0.18%
1개월 성능:
-1.55%
6개월 성능:
+34.41%
1년 성능:
-2.61%
1일 변동 폭
$160.26
$164.94
1주일 범위
$160.22
$174.87
52주 변동 폭
$102.97
$182.52
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
RGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
163.63 | 9.19B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
525.04 | 187.46B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
203.40 | 57.96B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.87 | 39.68B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
46.31 | 37.32B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
255.50 | 37.29B | 5.26B | 1.44B | 1.76B | 9.7713 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-01 | 개시 | HSBC Securities | Buy |
| 2025-09-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
3 Reasons to Sell RGEN and 1 Stock to Buy Instead - Finviz
Pharma News: Can Repligen Corporation navigate macro headwindsMarket Sentiment Review & Safe Entry Point Identification - mfd.ru
UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds - Insider Monkey
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Repligen Corp (RGEN) Shares Up 3.89% on Jan 21 - GuruFocus
Single-Use Bioprocessing Market Projected to Reach US$ 122.92 Billion by 2035, Supported by Expansion of Biomanufacturing Capacity Says Astute Analytica - GlobeNewswire Inc.
Slow Capital Inc. Has $5.89 Million Holdings in Repligen Corporation $RGEN - MarketBeat
Is It Too Late To Consider Buying Repligen Corporation (NASDAQ:RGEN)? - Yahoo Finance
Stephens Investment Management Group LLC Grows Stock Position in Repligen Corporation $RGEN - MarketBeat
Expert Outlook: Repligen Through The Eyes Of 5 Analysts - Benzinga
UBS raises Repligen stock price target to $200 on bioprocessing recovery - Investing.com
Why Repligen (RGEN) Shares Are Sliding Today - Finviz
Repligen Corp. Seeks M&A Opportunities - marketscreener.com
Published on: 2026-01-13 17:35:09 - Bộ Nội Vụ
Conestoga Capital Advisors LLC Has $127.91 Million Position in Repligen Corporation $RGEN - Defense World
Is Repligen Corporation stock gaining market share2025 Volatility Report & Growth Oriented Trading Recommendations - ulpravda.ru
Can Repligen Corporation stock hit record highs againJuly 2025 Levels & AI Powered Market Trend Analysis - Улправда
Repligen appoints Madaus as new board chair, Hunt to retire By Investing.com - Investing.com Canada
Repligen appoints Madaus as new board chair, Hunt to retire - Investing.com
Repligen Corporation Elects Dr. Martin D. Madaus as New Chair of the Board, Succeeding Tony Hunt - Quiver Quantitative
Repligen Corp Announces New Chair of the Board - TradingView — Track All Markets
Longtime Repligen leader steps down as new board chair takes over in 2026 - Stock Titan
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair - marketscreener.com
Repligen Corporation (RGEN): Investor Outlook with a 15% Upside Potential in the Bioprocessing Sector - DirectorsTalk Interviews
Institution Moves: How risky is Repligen Corporation RGN stock compared to peersMarket Risk Report & Risk Controlled Stock Pick Alerts - Bộ Nội Vụ
About Us - FinancialContent
Pacer Advisors Inc. Has $1.37 Million Position in Repligen Corporation $RGEN - MarketBeat
Allspring Global Investments Holdings LLC Lowers Stake in Repligen Corporation $RGEN - MarketBeat
Delta Investment Management LLC Buys Shares of 50,717 Repligen Corporation $RGEN - MarketBeat
Repligen Corporation (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why Repligen Corporation stock remains undervaluedFibonacci Retracement Levels & Free Dynamic Capital Growth - bollywoodhelpline.com
Is Repligen (RGEN) Quietly Recasting Its Gene Therapy Moat With New HiPer Viral Vector Resins? - simplywall.st
Riverbridge Partners LLC Sells 24,644 Shares of Repligen Corporation $RGEN - MarketBeat
Congress Asset Management Co. Boosts Stake in Repligen Corporation $RGEN - Defense World
Assenagon Asset Management S.A. Takes Position in Repligen Corporation $RGEN - MarketBeat
Can Repligen Corporation stock maintain growth trajectoryFed Meeting & Smart Allocation Stock Tips - Улправда
Texas Permanent School Fund Corp Has $3.13 Million Stock Holdings in Repligen Corporation $RGEN - MarketBeat
Will Repligen Corporation stock rally after Fed decisions2025 Winners & Losers & Free Technical Pattern Based Buy Signals - Улправда
Why Repligen Corporation (RGN) stock trades below fair valueJuly 2025 Drop Watch & Risk Managed Investment Signals - Bölüm Sonu Canavarı
Repligen (RGEN): Assessing Valuation After New Chromatography Resins Expand Its Gene Therapy Toolkit - simplywall.st
How institutional buying supports Repligen Corporation stockJuly 2025 Highlights & High Accuracy Investment Signals - Улправда
Insider Sell: Karen Dawes Sells Shares of Repligen Corp (RGEN) - GuruFocus
Repligen (NASDAQ:RGEN) Director Karen Dawes Sells 275 Shares - MarketBeat
REPLIGEN Director Karen A Dawes Sells 275 Shares - TradingView — Track All Markets
[Form 4] REPLIGEN CORP Insider Trading Activity - Stock Titan
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference - Yahoo Finance
Here’s Why Sands Capital Global Growth Fund Decided to Sell Repligen Corporation (RGEN) - Insider Monkey
The Bull Case For Repligen (RGEN) Could Change Following New Gene Therapy Chromatography Resin Launches - simplywall.st
Repligen (RGEN) Expands Product Line with High-Performance Chrom - GuruFocus
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
0.01%
자본화:
|
볼륨(24시간):